H Hygieia Jacqui's health & longevity concierge

Genetics / Risk Monitoring

What your gene results mean for tracking, bloods, scans, and interventions.

Genetic test report

1
TruDiagnostic genetic test 29.4.26
Open

Genetics / risk monitoring

Turn genetic findings into practical monitoring. This page is not a diagnosis — it helps decide what Hygieia should watch with blood tests, scans, wearables, and symptom tracking.

APOE e3/e4 MTHFR 677/1298 PEMT CBS GSTM1/GSTP1 COMT CYP1A2

Priority monitoring map

Priority Theme Main things to monitor Where Hygieia should track it Suggested cadence
Highest APOE e3/e4 ApoB, LDL-C, hs-CRP, cognition, sleep/recovery Blood Tests, Wearables, Coach, future cognition/risk review 3–6 month labs; monthly recovery/cognition review
Highest MTHFR / PEMT / CBS Homocysteine, folate, B12, B6, mood/energy/calm Blood Tests, Bio-state, Coach, pending pathology follow-up 3–6 month labs when active; review each new pathology result
Medium GSTM1 / GSTP1 Inflammation, liver function, exposure notes Blood Tests, Bio-state notes, environmental exposure tags 6–12 month review unless exposure/symptoms escalate
Medium COMT / CYP1A2 Caffeine timing, stress response, sleep latency, HRV Bio-state + Wearables Monthly or whenever behavior changes

How Hygieia should explain targets and actions

This section makes the logic explicit: for each condition, Hygieia should show the goal, the data it is using, the targets it is aiming for, and why the suggested actions follow.

Osteopenia
Bone density, support inputs, and fracture-risk logic.
Open

What Hygieia is trying to achieve

  • Slow further bone loss and reduce fracture risk.
  • Check whether bone-health inputs are actually adequate rather than assuming they are.
  • Make sure bone decisions are tied to real measurements like DEXA, vitamin D, calcium intake, protein intake, strength loading, and relevant blood markers.

What data it should use

  • DEXA / bone-density reports and trend over time.
  • 25-OH vitamin D, calcium, ALP, renal function, and other relevant bloods if present.
  • Protein intake, resistance training / impact loading, menopause / hormone context, and medication context.
  • Falls risk, frailty trajectory, and body-composition trend where available.

Targets Hygieia should state explicitly

  • Keep vitamin D in a clinician-agreed adequate range rather than low / borderline.
  • Keep protein and resistance-loading sufficient for bone preservation.
  • Repeat DEXA on an appropriate interval so progression or stability is visible.
  • Escalate attention if bone density worsens, fracture history appears, or supportive markers look weak.

Why the suggested actions follow

  • If DEXA is worsening, the target becomes preventing further decline and clarifying what is modifiable.
  • If vitamin D or nutrition support looks weak, correcting inputs becomes part of the plan because bone cannot be interpreted without them.
  • If loading / strength work is missing, that matters because bone maintenance is partly mechanical, not just nutritional.
  • If medication or hormonal context raises risk, Hygieia should surface that as a reason for faster follow-up or clinician review.
Lipids / ApoB
Cardiovascular risk reduction and plaque-burden logic.
Open

Goal + data used

  • Reduce atherogenic particle burden and lower future plaque risk.
  • Use ApoB, LDL-C, non-HDL, triglycerides, hs-CRP, Lp(a), CAC / imaging context, and medication response.
  • Treat calcium score 150, carotid plaque, and family/genetic context as reasons for stricter targets.

Targets + why actions follow

  • Current values: ApoB 0.6 g/L (2026-08-14); LDL 2.1 mmol/L (2026-08-14); non-HDL 2.6 mmol/L (2026-08-14). Targets should be explicit: ApoB <0.7 g/L, LDL <1.8 mmol/L (ideally ~1.4), non-HDL <2.2 mmol/L.
  • If ApoB remains above target, intensification logic should be visible. Already under target 0.7.
  • If plaque burden already exists, action urgency increases because this is not primary prevention in a vacuum. Current calcium score is 150.
Homocysteine / methylation
MTHFR-linked interpretation logic and nutrient-support targets.
Open

Goal + data used

  • Keep homocysteine in a healthier range and avoid treating folate/B12 markers in isolation.
  • Use homocysteine, folate, B12, B6, riboflavin context, CBC/MCV, symptoms, and genetics. Current homocysteine: 13.4 umol/L (2026-07-24).
  • Make new pathology results trigger a fresh interpretation cycle automatically.

Targets + why actions follow

  • If homocysteine is elevated, that should trigger more explicit methylation support review. Current homocysteine is 13.4 umol/L (2026-07-24).
  • If B12/folate seem normal but homocysteine remains high, Hygieia should explain why that still matters.
  • If mood, energy, or recovery worsen alongside the labs, the action rationale should be clearer and faster.
Inflammation
When hs-CRP and inflammatory context should change the plan.
Open

Goal + data used

  • Separate background low-risk inflammation from meaningful rises that need explanation.
  • Use hs-CRP, infection/injury context, autoimmune context if relevant, recovery data, and symptoms. Current hs-CRP: 0.27 mg/L (2026-08-14).
  • Interpret inflammation together with lipid/plaque and exposure context.

Targets + why actions follow

  • If inflammation rises, Hygieia should ask what changed, not just note the number. Current hs-CRP is 0.27 mg/L (2026-08-14).
  • If it rises together with poor recovery or symptoms, follow-up becomes more justified.
  • If it stays low, that should be shown as reassuring rather than ignored.
Insulin resistance / glucose stability
How fasting insulin, HbA1c, CGM, and glucose swings should shape action.
Open

Goal + data used

  • Reduce glucose variability and detect whether insulin burden is improving or worsening.
  • Use fasting insulin, fasting glucose, HbA1c, CGM patterns, triglycerides/HDL context, and weight/body-composition trend. Current insulin: 9 mU/L (2026-07-24); HbA1c: 28 mmol/mol (2026-08-14); Avg glucose: 5.4 mmol/L (2026-07-14); triglycerides: 1.2 mmol/L (2026-08-14); HDL: 1 mmol/L (2026-08-14).
  • Keep medication effects visible if agents like Mounjaro are in play.

Targets + why actions follow

  • If insulin is high despite a decent HbA1c, Hygieia should explain why that still matters. Current insulin is 9 mU/L (2026-07-24); HbA1c is 28 mmol/mol (2026-08-14).
  • If CGM swings are the main issue, recommendations should target variability, not only averages.
  • If medication improves the pattern, Hygieia should show that clearly so targets feel evidence-based, especially with Mounjaro in the current medication context.
APOE
Brain / lipid / vascular risk context
Open
HighestE3/E4

Why this matters

  • Your report says ApoE e3/e4 is associated with increased plasma cholesterol, lower antioxidant protection, and reduced synapse/neuron protection compared with more neutral patterns.
  • Review cadence: Lipids/inflammation every 3–6 months; cognition and recovery review monthly; deeper imaging only periodically when clinically useful.

Monitor in Hygieia

  • ApoB
  • LDL-C
  • non-HDL
  • Triglycerides
  • HDL
  • Lp(a)
  • hs-CRP
  • Cognition trend
  • Sleep/HRV recovery

Existing data already in Hygieia

  • Cholesterol result files already present in your records (e.g. 2025-07-16 dated bundle and archived cholesterol PDFs).
  • Wearables already track sleep / HRV / recovery patterns.

What Hygieia should do next

  • Keep lipids reviewed regularly, especially ApoB-focused tracking
  • Use sleep, exercise, and recovery tracking to reduce broader vascular/metabolic stress
  • Treat cognition drift, poor recovery, and rising inflammation as more meaningful signals
  • Coronary artery calcium scan over time if clinically appropriate
  • DEXA/body composition if metabolic risk context matters
MTHFR 677 + 1298
Methylation / homocysteine / folate pathway
Open
Highest677 AG heterozygous · 1298 GT heterozygous

Why this matters

  • Your report says MTHFR 677 is associated with ~30% reduced function and MTHFR 1298 with ~20% reduced function, increasing the relevance of methylfolate, riboflavin, and homocysteine tracking.
  • Review cadence: Homocysteine and methylation-support bloods whenever relevant pathology lands, then typically every 3–6 months if actively managing it.

Monitor in Hygieia

  • Homocysteine
  • Folate
  • B12
  • B6
  • CBC/MCV
  • MMA if B12 ambiguity exists
  • Mood / calm / energy trends

Existing data already in Hygieia

  • Pending homocysteine pathology result identified in myGov flow.
  • Bio-state page now tracks mood/calm/energy with biomarker context.

What Hygieia should do next

  • Review homocysteine whenever new bloods arrive
  • Treat elevated homocysteine as especially meaningful in your context
  • Keep methylation-related nutrient support visible in Hygieia
  • No primary scan driver; mainly blood-test and symptom/energy monitoring
PEMT
Choline / membrane / methylation support
Open
HighHigher choline need context

Why this matters

  • The report links your PEMT pattern with a higher choline requirement, which matters for methylation support and brain/lipid physiology.
  • Review cadence: Review together with homocysteine, lipids, liver context, and symptom clarity every 3–6 months.

Monitor in Hygieia

  • Homocysteine
  • Liver function context
  • Lipid trends
  • Diet / supplement adherence notes
  • Cognitive clarity notes

Existing data already in Hygieia

  • Can reuse cholesterol/lipid test files already in records.
  • Cognition and energy notes can be tracked in Bio-state / Coach.

What Hygieia should do next

  • Track whether choline support is in the plan
  • Use cognition, energy, and methylation markers together instead of treating PEMT in isolation
  • No routine scan; monitor indirectly through labs and symptoms
CBS
Homocysteine / transsulfuration / arsenic handling
Open
HighReduced-function context noted in report

Why this matters

  • The report says your CBS pattern is associated with reduced function for homocysteine handling, gut repair, brain health, and arsenic metabolism.
  • Review cadence: Review with each homocysteine cycle and re-check every 3–6 months when active symptoms or methylation work are in focus.

Monitor in Hygieia

  • Homocysteine
  • B6
  • Folate
  • Selenium context
  • Gut symptom notes
  • Exposure context where relevant

Existing data already in Hygieia

  • Pending homocysteine result is directly relevant here.
  • Bio-state notes can already track gut/brain/energy patterns.

What Hygieia should do next

  • Make B6 and homocysteine review part of recurring blood interpretation
  • Flag arsenic-heavy exposure context if relevant
  • Keep methylation and detox notes tied together in Hygieia
  • No primary scan; bloods plus exposure tracking matter more
GSTM1 / GSTP1
Detox / oxidative stress / smoke-pollution-heavy-metal sensitivity
Open
MediumGSTM1 null · GSTP1 rs1695 heterozygous AG

Why this matters

  • Your report links these with higher sensitivity to smoke, pollution, charred food, and some toxicant/heavy-metal burden contexts.
  • Review cadence: Inflammation/liver review every 6–12 months unless exposure or symptoms make it more urgent.

Monitor in Hygieia

  • hs-CRP
  • Liver function
  • Exposure notes
  • Symptom flare notes after smoke/pollution
  • Heavy metals only if exposure makes it relevant

Existing data already in Hygieia

  • Blood test system can already hold hs-CRP/liver panels when available.
  • Bio-state notes can capture exposure-triggered flares.

What Hygieia should do next

  • Log meaningful exposure events
  • Treat inflammation rises after exposures as more meaningful
  • Use environment/smoke/pollution tags in notes when symptoms flare
  • No routine scan; exposure + inflammation tracking is more useful
COMT
Catecholamine / estrogen / stress-response interpretation
Open
MediumGG / fast-function context in report

Why this matters

  • The report frames COMT as relevant for dopamine/adrenaline handling, estrogen metabolism context, and stress-response differences.
  • Review cadence: Behavioral review monthly or whenever stress, hormone, or caffeine patterns change.

Monitor in Hygieia

  • Mood
  • Stress reactivity
  • Caffeine response notes
  • Sleep impact
  • Hormone/cycle notes if relevant

Existing data already in Hygieia

  • Bio-state already tracks mood, calm, energy, and notes.
  • Wearables already track HRV and sleep.

What Hygieia should do next

  • Track stress-response patterns rather than overmedicalising the gene
  • Link caffeine, sleep, and mood together in Bio-state
  • No scan driver; mostly behavioral and symptom interpretation
CYP1A2
Caffeine timing / sleep / stress response
Open
MediumAA rapid caffeine metabolizer

Why this matters

  • The report says you are a rapid caffeine metabolizer, making caffeine timing and response worth tracking against sleep and mood.
  • Review cadence: Review monthly in Bio-state / Wearables, especially when caffeine habits change.

Monitor in Hygieia

  • Caffeine timing
  • Sleep latency
  • HRV
  • Resting HR
  • Mood / anxiety after caffeine

Existing data already in Hygieia

  • Wearables already provide sleep, HRV, and resting HR context.
  • Bio-state can hold caffeine-response notes.

What Hygieia should do next

  • Track caffeine use with same-day mood and sleep outcomes
  • Use wearable recovery metrics to see whether caffeine is helping or destabilising you
  • No scan driver